Eli Lilly's (LLY.US) new drug Kisunla for Alzheimer's disease approved for market by the European Union.

According to the Securities Times App, Lilly (LLY.US) announced on Thursday that the European Commission has granted marketing authorization for Kisunla (donanemab), a drug for treating early symptomatic Alzheimer's disease in adults, covering patients in the mild cognitive impairment and mild dementia stages.